Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-45
SponsorUniversity of Missouri-Columbia
About this trial
The purpose of this project is to examine key mechanisms contributing to sex-differences in hypoxic vasodilation and the impact of obesity, with particular emphasis on the sympathetic nervous system.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
BMI >18 kg/m2
Disqualifiers
Pregnancy, breastfeeding
Diagnosed sleep apnea or AHI >10 events/hr
Current smoking/Nicotine use
Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
Trial design
Design model
Single group
Treatments tested in this trial
Propranolol Hydrochloride
DrugRegional forearm blockade of β-adrenergic receptors at 20 mcg/dL/min via brachial artery catheter during normoxia and hypoxia exposures
Isoproterenol
DrugDose response (1, 3, 6, and 12 ng/dL/min) regional infusion to assess β-adrenergic receptor responsiveness
Phentolamine Mesylate
DrugThis infusion will be for 10 min before baseline measurement (12 mcg/dL/min) and continue the infusion at a maintenance rate (5 mcg/dL/min).
Norepinephrine
DrugRegional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
Treatment groups
72 Participants
are divided into 1 treatment groupGroup A: Hypoxia ExposureOther 4 interventions
Trial outcomes
Primary outcomes
1
Change in forearm vascular conductance with intra-arterial drug infusion
Vascular conductance is an index of vascular tone and is measured using a technique called venous occlusion plethysmography.
Time frame
Change from baseline to last 1-minute of drug infusionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov